Martin Shkreli failed to convince a federal judge to dismiss an antitrust lawsuit against him April 10, about a week after reports that the imprisoned “pharma bro” had been placed in solitary confinement.
Shkreli, Retrophin Inc., and two related companies are facing claims that they unlawfully shielded the blockbuster kidney drug Thiola from competition by refusing to put out samples that competing pharmaceutical companies must use, under federal law, to demonstrate the “bioequivalence” of their generics.
They will now have to undergo 90 days of limited discovery to determine whether plaintiff Spring Pharmaceuticals LLC has standing to sue by virtue ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.